working in the bioincubator and at TLS Foundation
RESEARCH FOUNDATION
TLS supports research activities in the Life Sciences and orphan diseases
working in the bioincubator and at TLS Foundation
since 2007 and 129 in 2021
collaborations and licenses since 2007
active patents since 2007
of financing generated and attracted by companies, research groups and TLS Foundation since 2007 (61 in 2021)
of turnover by the incubated and affiliated companies and by the research groups in 2021
of income from TLS incubation activities and services in 2021
Toscana Life Sciences is a non-profit organization active throughout the region in supporting research activities and promoting the creation of innovative companies in the Life Sciences field. Founded at the instigation of Tuscany’s principal university, clinical, industrial and financial institutions, the Foundation is based in Siena, in the historical “Torre Fiorentina” area, where Achille Sclavo founded the eponymous Istituto Sieroterapico e Vaccinogeno Toscano in 1904, and where important multinational vaccine companies now strategically choose to locate their primary research and development activities. An environment of excellence that is part of a regional panorama in which the Life Sciences play a strategic role.
TLS supports research activities in the Life Sciences and orphan diseases
An incubator that is unique on the national panorama for its facilitation of the business startup process in the Life Sciences sector
Responsible for implementing research valorization activities for the Tuscany Region through the UVaR office
Coordinator and manager of the activities of the Tuscany Life Sciences Cluster
The know-how and experience of TLS in support of an ambitious project of the Tuscany Region
TLS represents the Tuscany Region in the national Life Sciences cluster ALISEI
TLS takes care of the administrative and organisational aspects of the training courses in the field of the industrial biotechnologies and medical devices.
We help Life Sciences start-ups and companies to structure and ramp up their business project, offering support for business development, from writing a business plan to the search for investors. read more
The incubated companies have access to a package of general and consulting services for routine management and commercial development needs. read more
We help you evaluate the assets of your research project, protect them and valorize their results, providing advice regarding intellectual property and technology transfer. read more
TLS makes technological platforms and equipment for research available to companies, start-ups and external groups. read more
The bioincubator is the natural habitat for the birth and development of new companies (start-ups and spin-offs) in the Life Sciences sector. A "home" where research groups and companies that are already active can also find spaces, technological facilities and services to grow and compete in the Life Sciences market. A dynamic environment with over 3000 square meters of laboratories in which to capitalize on ideas and construct valuable relationships.
Joining the bioincubator is simple. Discover how we can help you give birth to your company or develop your research activities within our spaces. We operate in the following sectors: biotech, pharma, medical devices, nutraceuticals, cosmeceuticals and ICT applied to heathacare. You can apply for incubation or choose the TLS affiliation path to use our services.
TLS is one of the beneficiaries of an Advanced Grant supported by the European Research Council to investigate the role of gut microbiome in determining the efficacy of cancer vaccines.
The MAD Lab research team at TLS Foundation started activities in 2018 thanks to a 2.5 million euros ERC Advanced Grant focused on anti-microbialresistance and has grown quickly thanks to various funding sources received for tackling different health challenges
The project has the ambitious aim to conceptually allow the molecular prediction of diabetes type 2 and the response or resistance to molecular targeting interventions through the development of an innovative LOC (lab on chip) able to reveal important epigenotypes and rare genetic variations.
This grant aims to support young researchers in establishing independent laboratories focused on the cutting-edge oncology research. Specifically, we are interested in studying one of the most frequent tumours of B lymphocytes, B-cell chronic lymphocytic leukemia (CLL).
Supported also by philanthropic funds from a crowdfunding promoted by Coop (Unicoop Firenze; Unicoop Tirreno; Coop Centro Italia; Coop Alleanza 3.0; Coop Unione Amiatina e Coop Reno), the Data Science for Health (DaScH) Laboratory is the new TLS research unit for the application of data sciences and new technologies at the service of scientific research.
The quality control of botanicals requires in-depth knowledge of each phytocomplex and the definition of standards to ensure the authenticity of the product and its ingredients. Toscana Life Sciences has created a research and quality control structure capable of providing quali-quantitative protocols of widely consumed vegetable matrices in order to define their phytochemical profile, as well as both their consolidated and traditional use.
Supported also by philanthropic funds from a crowdfunding promoted by Coop (Unicoop Firenze; Unicoop Tirreno; Coop Centro Italia; Coop Alleanza 3.0; Coop Unione Amiatina e Coop Reno), the Data Science for Health (DaScH) Laboratory is the new TLS research unit for the application of data sciences and new technologies at the service of scientific research.
Toscana Life Sciences will coordinate the project in partnership with excellent actors from Germany, Spain, Polland and with the Fondazione Regionale per la Ricerca Biomedica (Lombardy Region), in order to elaborate guidelines supporting future research and innovation programmes concerning Personalised Medicine.
MammoScreen è il progetto europeo coordinato dalla Fondazione Toscana Life Sciences, che ha l’obiettivo di generare evidenza clinica sull’utilizzo di un mammografo basato sull’uso di microonde, invece che raggi X, per lo screening del tumore al seno.
Despite progress in high risk maternity management, Cerebral Palsy (CP) is the most common cause of physical disability in infants.
The health systems’ transformation from reactive treatment models to predictive and preventive systems, so as the personalised medicine paradigm implementation, requires cooperation and coordination among different actors, not only at European and Community level, with the aim of building an integrated action plan to foster the innovation in this field.